COV — CLEO Diagnostics Income Statement
0.000.00%
Last trade - 00:00- AU$48.19m
- AU$41.73m
- AU$1.18m
Annual income statement for CLEO Diagnostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0.11 | 0.6 | 1.18 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 0.023 | 1.69 | 4.21 | 5.08 |
| Operating Profit | -0.023 | -1.58 | -3.61 | -3.9 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.044 | -1.73 | -3.76 | -4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.044 | -1.73 | -3.76 | -4 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.044 | -1.73 | -3.76 | -4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.044 | -1.73 | -3.76 | -4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0 | -0.013 | -0.029 | -0.031 |